Q&A: Lonza's Christian Dowdeswell talks HPAPIs and the Oasmia deal
The mRNA boom has been beneficial for CDMOs, and Lonza is no different. It’s upgraded three of its sites — two in Europe and one in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
